In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

John Hodgson

Data Editor, Pharma

Cambridge, U.K
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better.
Advertisement
Set Alert for Articles By John Hodgson

Latest From John Hodgson

Regression To The Meanest: How Markets Value Pharma Stocks

Financial markets – the people and institutions that lend companies money and estimate their worth – see pharma companies as revenue-generating, profit-sharing black boxes. Growth earns companies a break from this simplistic view, but sooner or later market valuations of pharmas seem to regress to a mean based on revenue multiples. That mean is getting meaner.

Business Strategies Financing

Why We Examined These Companies

A look at the companies we included in our analysis.

BioPharmaceutical

Investors Ignore Trump On Pricing

When Donald Trump said on Jan. 11 that the drug companies were “getting away with murder” on pricing, some took his words seriously. But his shapeless message had no meaning for the markets. Investors glanced up from their screens momentarily but they don’t believe he will do anything about drug pricing.

Pricing Debate Government Payers

Distortion And Inflation In Measuring Pharma M&A

Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.

Deals Business Strategies

Pharma ExtrapolaTable: The 2016 Top 20

The pharma top 20 will not be definitively known until May when Takeda and Astellas publish their 2016 annual results, the last Big Pharma companies to do so. But for those who cannot wait until then (or even until Jan. 24 when Johnson & Johnson kicks the process off), Scrip’s ExtrapolaTable gives an early glance at the shape of pharma as another year rolls on.

Companies Sales & Earnings

Scrip 100: The Architecture Of A Top Heavy Industry

Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.

Commercial Market Intelligence
See All
Advertisement
UsernamePublicRestriction

Register